IP Library Granted Patent US 9,248,166
Granted Patent B2
US 9,248,166 · App. 14/203,383 · Granted Feb 2, 2016

Method for treating oncological diseases

Inventors: Dmitry Dmitrievich Genkin (St. Petersburg, RU); Viktor Veniaminovich Tets (St. Petersburg, RU); Georgy Viktorovich Tets (St. Petersburg, RU)
Assignee: CLS THERAPEUTICS LIMITED
A61K38/465C12Y301/21003
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,248,166
App. No.
14/203,383
Granted
Feb 2, 2016
Kind
B2
Abstract

A method to treat cancer and other malignant diseases, said method comprising parenterally administering an agent which destroys blood extracellular DNA into the systemic circulation of a cancer patient to slow down cancer growth. The agent is embodied in the form of a DNase enzyme and, more particularly, as a DNase I enzyme. Doses from 50,000-250,000,000 Kunitz units/day are administered for 5-360 days.

Claims (4)

1. A method of treating a cancer in a patient in need thereof, wherein said cancer is accompanied with elevation of blood extracellular DNA level, said method comprising parenterally administering to the patient a DNase enzyme in doses and regiments which provide blood plasma DNA-hydrolytic activity to exceed 150 Kunitz units per liter of plasma during more than 12 hours within 24 hours, wherein said cancer is a carcinoma.

2. The method according to claim 1 , wherein the DNase enzyme is human recombinant DNase.

3. A method of treating a cancer in a patient in need thereof, wherein said cancer is accompanied with elevation of blood extracellular DNA level, said method comprising parenterally administering to the patient a DNase enzyme in doses and regiments which provide depolymerization of blood extracellular DNA, wherein said cancer is a carcinoma.

4. The method according to claim 3 , wherein the DNase enzyme is human recombinant DNase.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 26, 2015
From: GENKIN, DMITRY DMITRIEVICH; TETS, VIKTOR VENIAMINOVICH; TETS, GEORGY VIKTOROVICH
To: CLS THERAPEUTICS LIMITED
Reel/Frame 035100/0328 →
Priority Claims (2)
RU PCT/RU2003/000304 · Jul 14, 2003 · national
RU RU2004108057 · Mar 12, 2004 · national
Continuity (4)
Continuation 12708914 · Feb 19, 2010
Continuation In Part 10564609
Continuation In Part 11919141
Related Publication 20140193389A1 · Jul 10, 2014